ES2194025T3 - Toxinas botulinicas multiples para tratar trastornos y enfermedades neuromusculares. - Google Patents

Toxinas botulinicas multiples para tratar trastornos y enfermedades neuromusculares.

Info

Publication number
ES2194025T3
ES2194025T3 ES94920108T ES94920108T ES2194025T3 ES 2194025 T3 ES2194025 T3 ES 2194025T3 ES 94920108 T ES94920108 T ES 94920108T ES 94920108 T ES94920108 T ES 94920108T ES 2194025 T3 ES2194025 T3 ES 2194025T3
Authority
ES
Spain
Prior art keywords
botulinic
toxins
treat disorders
neuromuscular diseases
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94920108T
Other languages
English (en)
Inventor
K Roger Aoki
Michael W Grayston
Steven R Carlson
Judith M Leon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of ES2194025T3 publication Critical patent/ES2194025T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

UN METODO Y COMPOSICION PARA EL TRATAMIENTO DE UN PACIENTE QUE SUFRA DE UNA ENFERMEDAD, DESORDEN O CONDICION INCLUYE LA ADMINISTRACION AL PACIENTE DE UNA CANTIDAD TERAPEUTICAMENTE ACEPTABLE DE UNA COMBINACION DE AL MENOS DOS NEUROTOXINAS SELECCIONADAS DE UN GRUPO QUE CONSTA DE TOXINA DE BOTULINA DE LOS TIPOS A, B, C, D, E, F Y G. LA CANTIDAD DE CADA NEUROTOXINA SELECCIONADA ADMINISTRADA SE SELECCIONA ADEMAS PARA CONTROLAR UNA DURACION DE UNA ACTIVIDAD TERAPEUTICA DE LA COMBINACION ADMINISTRADA.
ES94920108T 1993-06-10 1994-06-07 Toxinas botulinicas multiples para tratar trastornos y enfermedades neuromusculares. Expired - Lifetime ES2194025T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7503293A 1993-06-10 1993-06-10

Publications (1)

Publication Number Publication Date
ES2194025T3 true ES2194025T3 (es) 2003-11-16

Family

ID=22123106

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94920108T Expired - Lifetime ES2194025T3 (es) 1993-06-10 1994-06-07 Toxinas botulinicas multiples para tratar trastornos y enfermedades neuromusculares.

Country Status (8)

Country Link
US (1) US20010021695A1 (es)
EP (1) EP0702559B1 (es)
JP (2) JP4249802B2 (es)
AU (1) AU683275B2 (es)
CA (1) CA2164626C (es)
DE (1) DE69432299T2 (es)
ES (1) ES2194025T3 (es)
WO (1) WO1994028923A1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9120306D0 (en) 1991-09-24 1991-11-06 Graham Herbert K Method and compositions for the treatment of cerebral palsy
EP0654040A1 (en) * 1992-06-23 1995-05-24 Interactive Biologics Associates Pharmaceutical composition containing botulinum b complex
US6974578B1 (en) 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
AU2007202480B2 (en) * 1993-12-28 2009-01-29 Allergan, Inc. Method for treating pain associated with a muscle disorder
DE69434535T2 (de) * 1993-12-28 2006-07-20 Allergan, Inc., Irvine Toxische Komponente der Botulinumtoxine zur Modulation cholinergisch kontrollierter Sekretionen
US8187612B2 (en) 1993-12-28 2012-05-29 Allergan, Inc. Use of the neurotoxic component of a botulinum toxin for treating a spastic muscle
US8557256B2 (en) 1993-12-28 2013-10-15 Allergan, Inc. Treatment for cervical dystonia with the neurotoxic component of a botulinum toxin
US5766605A (en) * 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
US5756468A (en) 1994-10-13 1998-05-26 Wisconsin Alumni Research Foundation Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
AU6034396A (en) * 1995-06-06 1996-12-24 L. Bruce Pearce Improved compositions and methods for chemodenervation using neurotoxins
ATE216589T1 (de) * 1996-11-27 2002-05-15 William J Binder Neurotoxine zur behandlung von hauterkrankungen bei säugetieren
ATE320815T1 (de) 1997-07-15 2006-04-15 Univ Colorado Verwendung einer neurotoxintherapie zur behandlung von prostata erkrankungen
US9066943B2 (en) 1997-07-15 2015-06-30 The Regents Of The University Of Colorado Use of botulinum toxin therapy for treatment of urological neurological conditions
US7449192B2 (en) 1997-07-15 2008-11-11 The Regents Of The University Of Colorado Use of neurotoxin therapy for treatment of urologic and related disorders related to neurogenic bladder dysfunction
US7455845B2 (en) 1997-07-15 2008-11-25 The Regents Of The University Of Colorado Use of neurotoxin therapy for treatment of urologic and related disorders related to lowering elevated bladder pressure
US7470431B2 (en) 1997-07-15 2008-12-30 The Regents Of The University Of Colorado Use of neurotoxin therapy for treatment of urological-neurological disorders associated with prostate cancer
GB9721189D0 (en) * 1997-10-08 1997-12-03 Speywood Lab The Limited Analgesic conjugates
WO1999037326A1 (en) 1998-01-26 1999-07-29 University Of Massachusetts Biologically active hemagglutinin from type a clostridium botulinum and methods of use
TW574036B (en) 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
CA2347828A1 (en) * 1998-10-27 2000-05-04 Mayo Foundation For Medical Education And Research Methods for enhancing wound healing
DE19856897A1 (de) * 1998-12-10 2000-06-15 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum zur Unterdrückung von Schnarchgeräuschen
GB9907429D0 (en) 1999-03-31 1999-05-26 Microbiological Res Authority Modulation of C-fibre activity
DE19925739A1 (de) * 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
DE10035156A1 (de) * 2000-07-19 2002-02-07 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Proteinkomplex als Vehikel für oral verfügbare Protein-Arzneimittel
US6423319B1 (en) * 2000-10-04 2002-07-23 Allergan Sales, Inc. Methods for treating muscle injuries
US7608625B2 (en) 2003-03-13 2009-10-27 Eisai R & D Management Co., Ltd. Method for treating bruxism and bruxism-related diseases
US8343929B2 (en) * 2004-09-23 2013-01-01 Toxcure, Inc. Treating neoplasms with neurotoxin
CA2875562A1 (en) * 2004-09-23 2006-03-30 Toxcure, Inc. Treating neoplasms with neurotoxin
WO2008036060A2 (en) 2005-04-05 2008-03-27 Allergan, Inc. Clostridial toxin activity assays
US8105611B2 (en) * 2005-06-17 2012-01-31 Allergan, Inc. Treatment of autoimmune disorder with a neurotoxin
FR2896693B1 (fr) * 2006-01-27 2008-03-14 Sod Conseils Rech Applic Composition comprenant plusieurs toxines botuliques
WO2009139739A1 (en) * 2006-02-14 2009-11-19 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions comprising a combination of botulinum toxin a and botulinum toxin b for treating conditions characterized by unwanted or excessive presynaptic neuronal activity or secretion
US20130171122A1 (en) * 2011-12-29 2013-07-04 Allergan, Inc. Endopeptidase and neurotoxin combination treatment of bladder disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9120306D0 (en) * 1991-09-24 1991-11-06 Graham Herbert K Method and compositions for the treatment of cerebral palsy
EP0654040A1 (en) * 1992-06-23 1995-05-24 Interactive Biologics Associates Pharmaceutical composition containing botulinum b complex

Also Published As

Publication number Publication date
EP0702559A1 (en) 1996-03-27
CA2164626C (en) 2004-11-23
WO1994028923A1 (en) 1994-12-22
DE69432299T2 (de) 2003-12-11
US20010021695A1 (en) 2001-09-13
JP4249802B2 (ja) 2009-04-08
DE69432299D1 (de) 2003-04-24
AU683275B2 (en) 1997-11-06
AU7101894A (en) 1995-01-03
JPH08511537A (ja) 1996-12-03
EP0702559B1 (en) 2003-03-19
CA2164626A1 (en) 1994-12-22
JP2006052227A (ja) 2006-02-23

Similar Documents

Publication Publication Date Title
AU762481C (en) Vitamin D and its analogs in the treatment of tumors and other hyperproliferative disorders
NO20013727D0 (no) Anvendelse av Botulinumtoksin B for fremstilling av et medikament
DK0682514T3 (da) Anvendelse af lokalanæstetiske midler til fremstilling af et lægmiddel til behandling af bronchial astma
ES2168302T3 (es) Tratamiento de trastornos y estados neuromusculares con toxina botulinica de serotipo e.
ES2162615T3 (es) Metodo para tratar o prevenir diabetes de tipo 1 mediante la administracion oral de insulina.
ATE157257T1 (de) Verstärkung der unterdrückungsregulation von autoimmunkrankheiten durch orale oder enterale verabreichung von autoantigenen
DE69434211D1 (de) Phenylacetate und derivate, allein oder in kombination mit anderen verbindungen, zur behandlung von neoplastischen und anderen erkrankungen
BR9813524A (pt) Processos para tratamento de toxicidades associadas com a administração de um agente terapêutico a um mamìfero, para tratamento de toxicidades associadas com a exposição de um mamìfero à terapia de radiação, para tratamento de neuro- ou nefrodistúrbios em um humano, e, para tratamento de distúrbios e sintomas clìnicos associados com diabetes do tipo i ou do tipo ii em um humano
DE69533112T2 (de) Verwendung von flavolignanen zur herstellung von medikamenten mit antiproliferativer aktivität in gebärmutter,brust,eierstöcken
ES2137948T3 (es) Sistema avanzado de administracion de medicamentos y metodo de tratamiento de trastornos psiquiatricos, neurologicos y otros con carbamacepina.
NO20001087L (no) Medikament for forlengelse av muskelfunksjon eller behandling av muskelforstyrrelser eller -sykdommer
ES2060941T3 (es) Uso de nicotina para la fabricacion de un estuche para el tratamiento de condiciones susceptibles de dicho tratamiento.
PT668763E (pt) Utilizacao de fenserina para a preparacao de medicamentos para tratar doencas do conhecimento
DK0713701T3 (da) 2-Brommelatonin til behandling af søvnforstyrrelser
NO990912D0 (no) Terapeutiske kombinasjoner av PAR-antagonister og RXR-antagonister og deres anvendelse
ES2058592T3 (es) El uso de sustancias activas fisiologicamente para la fabricacion de medicamentos para enfermedades cerebrales y neuronales.
DE69424777D1 (de) 3,4-diarylchromane zur behandlung von dermatitis
Latha et al. Efficacy of yoga therapy in the management of headaches.
IL73292A0 (en) Kit for administering gangliosides and derivatives thereof by inhalation and pharmaceutical composition suitable therefor
YU61598A (sh) Tretmani bolesti uz korišćenje citokina
ATE89737T1 (de) Behandlung von leukozytstoerungen mit gm-csf.
MX9704887A (es) Composiciones farmaceuticas para el tratamiento de trastornos depresivos.
Davis et al. Constant F, Guiilemin F, Collin JF, Boulange M. Use of spa therapy to improve the quality of life of chronic low back pain patients. Medical Care
ATE247468T1 (de) Kombinationstherapie von topoisomerase ii toxinen und bis-dioxypiperazinderivaten
Naukkarinen et al. Parenterally administered procaine chloride in the treatment of somatizing depressed patients: An uncontrolled pilot study.